Goodwin advised Jiangsu Hengrui Medicine as it entered into an exclusive global license agreement with TG Therapeutics. Under the terms of the agreement, Jiangsu Hengrui will…
Jiangsu Hengrui Medicine and TG Therapeutics’ Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program
